Vision scientists have identified a key player in macular degeneration (MD), raising hope for a treatment for the currently incurable blinding disease.
The studies reveal how light-damaged eyes invoke an out-of-control immune response, resulting in white blood cells invading the retina and leaving behind proteins that kill the light sensitive vision cells.
“When the cells in our eyes are damaged, the immune response kicks in and sends macrophages—white blood cells that 'eat' invading or dead cells—to clean up the mess,” say the researchers. “If the immune system is not properly regulated, the invading cells linger and call in even more macrophages—literally, 'big eaters.'”
“Our study shows that the macrophages deposit a complex of proteins on retinal cells, which then kills them. The macrophages clean up the remains, and if the immune system doesn't control the process, the light-sensitive cells die and get eaten away by the macrophages.”
In macular degeneration macrophages attack vision cells in the fovea—a 'pit' at the back of the eye, which is the critical region for detailed vision, enabling us to do things like read, recognize faces and see small detail.
The researchers say that previous research, mostly done in Australia, showed that these 'rogue' macrophages are involved in macular degeneration, but it wasn't clear what was driving them or how they contributed to degeneration.
By studying light-damaged eyes in rats, the Vision Centre team found that when the retina is damaged by bright light, it increases its production of a molecule known as Ccl2, which attracts macrophages into the eye. The team has shown that peak levels of Ccl2 coincide with the highest death rates of vision cells.
The macrophages then bring in another molecule, known as C3. This causes the formation of a complex of molecules called a 'membrane attack complex', which coats the light-sensitive cells, causing them to die. The macrophages then eat up the remains.
“We knew that the membrane attack complex is present in macular degeneration, but we didn't know how it got there. Now we know that it is started by macrophages that are attracted by Ccl2,” says Professor Jan Provis, who heads the team.
“It was discovered in 2005 that many sufferers of macular degeneration have a defect in a factor that breaks down C3, but that research did not show how the C3 gets into the retina. Our study shows that it is brought in by the macrophages, attracted by Ccl2.”
Identifying Ccl2 leads to a potential path for treating the dry form of macular degeneration: “Pinning down Ccl2 gives us a target—we can start looking for ways to block Ccl2, and so prevent the attraction of macrophages into the retina and the accumulation of C3”.
The team is currently exploring whether shining a soft infra-red light on light-damaged eyes can inhibit Ccl2 growth. If this works, it will lead to a cheap and non-intrusive way of slowing down macular degeneration. The early results are promising, they say.
The research team has published two journal articles that are related to the topic in Investigative Ophthalmology and Visual Science.
Adapted from the Vision Center
View all news updates for macular degeneration
Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.
Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.